北京元延医药科技

北京元延医药科技 (Beijing Yuanyan Pharmaceutical Technology) is a high-tech pharmaceutical company founded in 2009 and headquartered in Beijing, China. The company specializes in the research, development, production, sales, and technology transfer of chemical APIs, pharmaceutical intermediates, and drug formulations. Operating as both a generic drug developer and a contract research organization (CRO), it provides comprehensive services ranging from pre-clinical formulation development to clinical trial management and consistency evaluation. Beijing Yuanyan Pharmaceutical Technology has successfully commercialized several generic products, including sitagliptin phosphate tablets for type 2 diabetes and olmesartan medoxomil + hydrochlorothiazide tablets for hypertension, and maintains advanced technology platforms for solid dispersion and liposome formulations.